Lipid Lowering Drugs in Acute Coronary Syndromes (ACS)

Natalie Arnold; Wolfgang Koenig

doi:10.1007/s11883-023-01163-6

Lipid Lowering Drugs in Acute Coronary Syndromes (ACS)

Standard

Lipid Lowering Drugs in Acute Coronary Syndromes (ACS). / Arnold, Natalie; Koenig, Wolfgang.

In: CURR ATHEROSCLER REP, Vol. 25, No. 12, 12.2023, p. 939-946.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Arnold, N & Koenig, W 2023, 'Lipid Lowering Drugs in Acute Coronary Syndromes (ACS)', CURR ATHEROSCLER REP, vol. 25, no. 12, pp. 939-946. https://doi.org/10.1007/s11883-023-01163-6

APA

Arnold, N., & Koenig, W. (2023). Lipid Lowering Drugs in Acute Coronary Syndromes (ACS). CURR ATHEROSCLER REP, 25(12), 939-946. https://doi.org/10.1007/s11883-023-01163-6

Vancouver

Arnold N, Koenig W. Lipid Lowering Drugs in Acute Coronary Syndromes (ACS). CURR ATHEROSCLER REP. 2023 Dec;25(12):939-946. https://doi.org/10.1007/s11883-023-01163-6

Bibtex

@article{22e49cb654cb4cff864282b60200a2a2,

title = "Lipid Lowering Drugs in Acute Coronary Syndromes (ACS)",

abstract = "PURPOSE OF REVIEW: The purpose of this review is to critically discuss whether more aggressive lipid-lowering strategies are needed in patients with acute coronary syndromes (ACS).RECENT FINDINGS: Currently, available data on early (in-hospital/discharge) administration of potent lipid-lowering drugs, such as proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in patients during the vulnerable post-ACS phase, have clearly demonstrated clinical efficacy of the {"}strike early and strike strong{"} approach not only for rapid reduction of low-density lipoprotein cholesterol (LDL-C) to unprecedentedly low levels, but also for associated favorable composition of coronary plaque. Intensive lipid-lowering therapy with rapid achievement of the LDL-C treatment goal in ACS patients seems reasonable. However, whether such profound LDL-C reduction would result in additional benefit on the reduction of future CV events still has to be established. Thus, data addressing CV outcomes in such vulnerable patients at extreme CV risk are urgently needed.",

keywords = "Humans, Proprotein Convertase 9, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Acute Coronary Syndrome/drug therapy, Cholesterol, LDL, Hypolipidemic Agents/therapeutic use, Anticholesteremic Agents/therapeutic use",

author = "Natalie Arnold and Wolfgang Koenig",

note = "{\textcopyright} 2023. The Author(s).",

year = "2023",

month = dec,

doi = "10.1007/s11883-023-01163-6",

language = "English",

volume = "25",

pages = "939--946",

journal = "CURR ATHEROSCLER REP",

issn = "1523-3804",

publisher = "Current Medicine Group",

number = "12",

}

RIS

TY - JOUR

T1 - Lipid Lowering Drugs in Acute Coronary Syndromes (ACS)

AU - Arnold, Natalie

AU - Koenig, Wolfgang

PY - 2023/12

Y1 - 2023/12

N2 - PURPOSE OF REVIEW: The purpose of this review is to critically discuss whether more aggressive lipid-lowering strategies are needed in patients with acute coronary syndromes (ACS).RECENT FINDINGS: Currently, available data on early (in-hospital/discharge) administration of potent lipid-lowering drugs, such as proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in patients during the vulnerable post-ACS phase, have clearly demonstrated clinical efficacy of the "strike early and strike strong" approach not only for rapid reduction of low-density lipoprotein cholesterol (LDL-C) to unprecedentedly low levels, but also for associated favorable composition of coronary plaque. Intensive lipid-lowering therapy with rapid achievement of the LDL-C treatment goal in ACS patients seems reasonable. However, whether such profound LDL-C reduction would result in additional benefit on the reduction of future CV events still has to be established. Thus, data addressing CV outcomes in such vulnerable patients at extreme CV risk are urgently needed.

AB - PURPOSE OF REVIEW: The purpose of this review is to critically discuss whether more aggressive lipid-lowering strategies are needed in patients with acute coronary syndromes (ACS).RECENT FINDINGS: Currently, available data on early (in-hospital/discharge) administration of potent lipid-lowering drugs, such as proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in patients during the vulnerable post-ACS phase, have clearly demonstrated clinical efficacy of the "strike early and strike strong" approach not only for rapid reduction of low-density lipoprotein cholesterol (LDL-C) to unprecedentedly low levels, but also for associated favorable composition of coronary plaque. Intensive lipid-lowering therapy with rapid achievement of the LDL-C treatment goal in ACS patients seems reasonable. However, whether such profound LDL-C reduction would result in additional benefit on the reduction of future CV events still has to be established. Thus, data addressing CV outcomes in such vulnerable patients at extreme CV risk are urgently needed.

KW - Humans

KW - Proprotein Convertase 9

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use

KW - Acute Coronary Syndrome/drug therapy

KW - Cholesterol, LDL

KW - Hypolipidemic Agents/therapeutic use

KW - Anticholesteremic Agents/therapeutic use

U2 - 10.1007/s11883-023-01163-6

DO - 10.1007/s11883-023-01163-6

M3 - SCORING: Review article

C2 - 38015336

VL - 25

SP - 939

EP - 946

JO - CURR ATHEROSCLER REP

JF - CURR ATHEROSCLER REP

SN - 1523-3804

IS - 12

ER -